A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis

Summary

This was a randomized, double blind, placebo controlled, parallel group study in 129 subjects with moderate to severe psoriasis with a PASI score of at least 10. Following run-in, subjects were randomized and received either oral 30 mg ZPL-3893787 once daily or placebo once daily for 12 weeks.

Timeline

Start

2016-01-11

Primary completion

2016-12-22

Completion

2016-12-22

Outcome

Missed primary endpoint

registry MEAN ZPL-389: -28.043 (Standard Deviation 38.4436) percentage change NCT02618616 ↗

registry analysis (other test); ZPL-389 vs Placebo; p = 0.8495 NCT02618616 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ADRIFORANT	Small molecule	30 mg	Oral

Indications